News

A machine learning model taking into account markers of inflammation and clinical data may accurately predict whether people with generalized myasthenia gravis (gMG) are likely to see their disease symptoms ease after six months of standard treatment. Researchers described the new tool in the study, “Interpretable…

Myasthenia gravis (MG) patients who are women or have a tumor in the thymus gland are more likely to require intensive care due to disease exacerbation, a retrospective study in Finland suggests. Patients with late-onset disease in whom disease symptoms become apparent after the age of 50 were also…

The first patient has been dosed in a proof-of-concept clinical trial evaluating CNP-106, an immune-modifying nanoparticle that’s designed to reprogram the immune system in people with generalized myasthenia gravis (gMG). The Phase 1b/2a trial NCT06106672), sponsored by CNP-106’s developer Cour Pharmaceuticals, will assess the safety, tolerability, efficacy,…

The China National Food and Drug Administration has accepted and placed under priority review an application from Remegen seeking approval of telitacicept as a treatment for generalized myasthenia gravis (gMG). That’s according to a press release from Remegen, a commercial-stage biotechnology company that’s developing the treatment…

The healthcare costs of myasthenia gravis (MG) are high, according to a study from Denmark, Finland, and Sweden, and even higher for women and patients with very severe symptoms or coexisting conditions such as mental health problems or severe infections. A large portion of direct costs in all three…

Among people with myasthenia gravis (MG), the degree of daily activity impairment is greater for those with more severe and more widespread muscle weakness, according to real-world data from a survey of physicians in the U.S. and Europe. However, the study — which involved clinicians treating more than…

A bacterial enzyme called CU43 potently mitigates the impact of the self-reactive antibodies that drive myasthenia gravis (MG) and other autoimmune diseases, according to data from a preclinical study. The research team, led by scientists at Emory University in Georgia, in collaboration with researchers at Rockefeller University in New…

The new UCB Myasthenia Gravis Scholarship, launched by the Belgium-based biopharmaceutical company, is aiming to help myasthenia gravis (MG) patients and their family members in the U.S. to continue their education or learn new skills by covering educational expenses — with program awards totaling up to $150,000. “We…

Johnson & Johnson’s nipocalimab appears to be safe and to ease symptoms of generalized myasthenia gravis (gMG) in adolescents with antibodies against the acetylcholine receptor, the most common type of MG-causing antibody, according to six-month data from an open-label clinical trial. The Phase 2/3 Vibrance-MG study…

Two doses of inebilizumab, Amgen’s antibody-based therapy, led to sustained reductions in the severity of generalized myasthenia gravis (gMG) among patients for up to six months, meeting the primary goal of an ongoing Phase 3 clinical trial. The trial, called MINT (NCT04524273), demonstrated that inebilizumab’s benefits extend…